Six-month data show gains with CardioFit

September 2008
Medical Device Daily;9/17/2008, Vol. 12 Issue 199, p8
The article reports on the announcement by BioControl Medical regarding the publication of six-month data for eight of the more than 30 patients who participated in the European pilot study of its CardioFit device for congestive heart failure (CHF). According to Doctor Ehud Cohen, chief executive officer (CEO) of BioControl Medical, their implantable neuromodulation technology is being applied to develop therapeutic devices in urology and for the treatment of CHF.


Related Articles

  • BioControl Medical Launches the INOVATE-HF IDE Study of Its CardioFit(r) System for Heart Failure.  // Biomedical Market Newsletter;5/28/2011, p697 

    The article reports on the launching of increase of vagal tone in heart failure (INOVATE-HF) clinical study from BioControl Medical for heart failure. As stated, INOVATE-HF is a clinical study that determines the safety and efficacy of CardioFit system which is an implantable electrical...

  • Industry Watch.  // Medical Design Technology;Feb2007, Vol. 11 Issue 2, p16 

    The article reports developments pertaining to the medical devices industry in the U.S. Patients who suffered certain types of arrhythmias can already benefit from treatment with an ablation catheter. BioControl Medical is enrolling patients for an international, multi-center, open-label...

  • Six-month data show gains with CardioFit.  // Cardiovascular Devices & Drugs;Oct2008, Vol. 14 Issue 10, p13 

    The article reports on the publication of data for eight of the more than 30 patients who participated in the European pilot study of BioControl Medical's pilot study of its CardioFit device for congestive heart failure (CHF). The results were published in the September 2008 issue of the...

  • First patient enrolled in INOVATE-HF for CardioFit. PEDERSEN, AMANDA // Medical Device Daily;4/27/2011, Vol. 15 Issue 81, p1 

    The article reports that BioControl Medical has enrolled the first patient for its Increase of Vagal Tone in Heart Failure (INOVATE-HF) study at Northwest Texas Heart Hospital in Amarillo, Texas. The study aims to determine the efficacy and safety of the company's CardioFit system, an...

  • Two more sites join up for CardioFit trial.  // Cardiovascular Device Update;Sep2007, Vol. 13 Issue 9, p16 

    The article reports that University Hospital Mannheim in Germany and Ospedali Riuniti di Bergamo in Italy joined the CardioFit system trial. According to BioControl Medical, surgeons and cardiologists implanted the device in the first patients who enrolled. Electrical impulses to the vagus nerve...

  • Two more sites join in CardioFit trial.  // Medical Device Daily;8/3/2007, Vol. 11 Issue 147, p8 

    The article reports that two more clinical trial sites has been opened for the CardioFit system, a device for the treatment of advanced congestive heart failure developed by BioControl Medical. Cardiologists and surgeons at University Hospital Mannheim in Germany and Ospedali Riuniti di Bergamo...

  • CE mark for CardioFit.  // Medical Device Daily;1/8/2009, Vol. 13 Issue 4, p9 

    The article reports on a CE-mark certification issued by KEMA for the CardioFit system developed by advanced implantable devices manufacturer BioControl Medical. CardioFit was designed to treat NYHS class II-III heart failure patients with no symptomatic improvement from standard evidence-based...

  • Implantable Left Ventricular Assist Devices. Goldstein, Daniel J.; Oz, Mehmet C.; Rose, Eric A. // New England Journal of Medicine;11/19/98, Vol. 339 Issue 21, p1522 

    Focuses on the development of implantable left ventricular assist devices for patients with cardiac disease such as congestive heart failure. Historical perspective; Wearable devices; Devices as a bridge to transplantation; Complications including hemorrhage, right-sided heart failure, and...

  • Good News and Bad News: The Cost of Mending a Broken Heart. Williams, David // Medical Device Technology;Jan/Feb2003, Vol. 14 Issue 1, p8 

    Discusses the technology known as destination therapy, which refers to the use of Thoratec Corp.'s Heartmate Left-Ventricular-Assist System to treat congestive heart failure, as well as the economics and the philosophy of left-ventricular-assist systems. U.S. Food and Drug Administration's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics